Cocaine metabolism accelerated by a re-engineered human butyrylcholinesterase

Hong Sun, Maryann L. Shen, Yuan-Ping Pang, Oksana Lockridge, William Stephen Brimijoin

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Plasma butyrylcholinesterase (BChE) is important in the metabolism of cocaine, but natural human BChE has limited therapeutic potential for detoxication because of low catalytic efficiency with cocaine. Here we report pharmacokinetics of cocaine in rats treated with A328W/Y332A BChE, an excellent cocaine hydrolase designed with the aid of molecular modeling. Compared with wild-type BChE, this enzyme hydrolyzes cocaine with 40-fold improved kcat (154 min-1 versus 4.1 min-1) and only slightly increased KM (18 μM versus 4.5 μM). In rats given this hydrolase (3 mg/kg i.v.) 10 min before cocaine challenge (6.8 mg/kg i.v.), cocaine half-life was reduced from 52 min to 18 min. Mirroring the reductions of plasma cocaine were large increases in benzoic acid, a product of BChE-mediated cocaine hydrolysis. All other pharmacokinetic parameters confirmed a large, dose-dependent acceleration of cocaine removal by the injected cocaine hydrolase. These results show that A328W/Y332A, an efficient cocaine hydrolase in vivo as well as in vitro, might promote cocaine detoxication in a clinical setting.

Original languageEnglish (US)
Pages (from-to)710-716
Number of pages7
JournalJournal of Pharmacology and Experimental Therapeutics
Volume302
Issue number2
DOIs
StatePublished - 2002

Fingerprint

Butyrylcholinesterase
Cocaine
Hydrolases
Pharmacokinetics
Benzoic Acid
Half-Life

ASJC Scopus subject areas

  • Pharmacology

Cite this

Cocaine metabolism accelerated by a re-engineered human butyrylcholinesterase. / Sun, Hong; Shen, Maryann L.; Pang, Yuan-Ping; Lockridge, Oksana; Brimijoin, William Stephen.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 302, No. 2, 2002, p. 710-716.

Research output: Contribution to journalArticle

@article{491ca50ca038413f815423e02df291ed,
title = "Cocaine metabolism accelerated by a re-engineered human butyrylcholinesterase",
abstract = "Plasma butyrylcholinesterase (BChE) is important in the metabolism of cocaine, but natural human BChE has limited therapeutic potential for detoxication because of low catalytic efficiency with cocaine. Here we report pharmacokinetics of cocaine in rats treated with A328W/Y332A BChE, an excellent cocaine hydrolase designed with the aid of molecular modeling. Compared with wild-type BChE, this enzyme hydrolyzes cocaine with 40-fold improved kcat (154 min-1 versus 4.1 min-1) and only slightly increased KM (18 μM versus 4.5 μM). In rats given this hydrolase (3 mg/kg i.v.) 10 min before cocaine challenge (6.8 mg/kg i.v.), cocaine half-life was reduced from 52 min to 18 min. Mirroring the reductions of plasma cocaine were large increases in benzoic acid, a product of BChE-mediated cocaine hydrolysis. All other pharmacokinetic parameters confirmed a large, dose-dependent acceleration of cocaine removal by the injected cocaine hydrolase. These results show that A328W/Y332A, an efficient cocaine hydrolase in vivo as well as in vitro, might promote cocaine detoxication in a clinical setting.",
author = "Hong Sun and Shen, {Maryann L.} and Yuan-Ping Pang and Oksana Lockridge and Brimijoin, {William Stephen}",
year = "2002",
doi = "10.1124/jpet.302.2.710",
language = "English (US)",
volume = "302",
pages = "710--716",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Cocaine metabolism accelerated by a re-engineered human butyrylcholinesterase

AU - Sun, Hong

AU - Shen, Maryann L.

AU - Pang, Yuan-Ping

AU - Lockridge, Oksana

AU - Brimijoin, William Stephen

PY - 2002

Y1 - 2002

N2 - Plasma butyrylcholinesterase (BChE) is important in the metabolism of cocaine, but natural human BChE has limited therapeutic potential for detoxication because of low catalytic efficiency with cocaine. Here we report pharmacokinetics of cocaine in rats treated with A328W/Y332A BChE, an excellent cocaine hydrolase designed with the aid of molecular modeling. Compared with wild-type BChE, this enzyme hydrolyzes cocaine with 40-fold improved kcat (154 min-1 versus 4.1 min-1) and only slightly increased KM (18 μM versus 4.5 μM). In rats given this hydrolase (3 mg/kg i.v.) 10 min before cocaine challenge (6.8 mg/kg i.v.), cocaine half-life was reduced from 52 min to 18 min. Mirroring the reductions of plasma cocaine were large increases in benzoic acid, a product of BChE-mediated cocaine hydrolysis. All other pharmacokinetic parameters confirmed a large, dose-dependent acceleration of cocaine removal by the injected cocaine hydrolase. These results show that A328W/Y332A, an efficient cocaine hydrolase in vivo as well as in vitro, might promote cocaine detoxication in a clinical setting.

AB - Plasma butyrylcholinesterase (BChE) is important in the metabolism of cocaine, but natural human BChE has limited therapeutic potential for detoxication because of low catalytic efficiency with cocaine. Here we report pharmacokinetics of cocaine in rats treated with A328W/Y332A BChE, an excellent cocaine hydrolase designed with the aid of molecular modeling. Compared with wild-type BChE, this enzyme hydrolyzes cocaine with 40-fold improved kcat (154 min-1 versus 4.1 min-1) and only slightly increased KM (18 μM versus 4.5 μM). In rats given this hydrolase (3 mg/kg i.v.) 10 min before cocaine challenge (6.8 mg/kg i.v.), cocaine half-life was reduced from 52 min to 18 min. Mirroring the reductions of plasma cocaine were large increases in benzoic acid, a product of BChE-mediated cocaine hydrolysis. All other pharmacokinetic parameters confirmed a large, dose-dependent acceleration of cocaine removal by the injected cocaine hydrolase. These results show that A328W/Y332A, an efficient cocaine hydrolase in vivo as well as in vitro, might promote cocaine detoxication in a clinical setting.

UR - http://www.scopus.com/inward/record.url?scp=0036073873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036073873&partnerID=8YFLogxK

U2 - 10.1124/jpet.302.2.710

DO - 10.1124/jpet.302.2.710

M3 - Article

C2 - 12130735

AN - SCOPUS:0036073873

VL - 302

SP - 710

EP - 716

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -